Development of novel therapeutic approaches addressing infectious and autoimmune diseases as well as cancers via immune cell-specific targeting.
Dr. Marcus Furch
Dr. Robert Gieseler v. d. Crone
Rodos BioTarget Receives Growth Financing of EUR 2.6 m
Rodos BioTarget GmbH (RBT) is pleased to announce that it has in 2012 successfully realized corporate investment actions in the amount of EUR 2.6 million, with additional option payments attached to its milestones for 2013. Institutional investors participating in this round include the InvestImpuls-Fonds of the…
Rodos BioTarget Receives Start-up Financing by High-Tech Gruenderfonds and hannover innovations fonds
Novel platform technology for Targeted Drug Delivery set to enable successful treatment of various infectious diseases and cancers. Rodos BioTarget GmbH [RBT] successfully closed a start-up financing round with High-Tech Gruenderfonds and hannover innovation fonds [hif]. In order to address various chronic infectious…
29. Dec 2008